Hyperfine 2025 Q3 Earnings Wider Net Loss Despite Sequential Revenue Growth

Hyperfine (HYPR) reported Q3 2025 earnings on Nov 14, 2025, with revenue declining 5.7% year-over-year to $3.44 million and a net loss widening by 6.7% to $11.02 million. The results missed analyst expectations for revenue by $0.12 million and EPS by $0.04. Management raised Q4 revenue guidance to $5–6 million, reflecting confidence in next-gen Swoop system adoption and operational efficiency.

Revenue

Device revenue amounted to $2.89 million, while service revenue contributed $546,000, totaling $3.44 million. The 5.7% year-over-year decline contrasts with a 27% sequential increase, driven by next-gen Swoop system sales and a $361,000 average selling price.

Earnings/Net Income

The company maintained an EPS of $-0.14, but the net loss expanded to $11.02 million in Q3 2025, a 6.7% increase from the $10.33 million loss in Q3 2024. The sustained losses over five consecutive years highlight ongoing financial challenges despite improved gross margins.

Post-Earnings Price Action Review

The strategy of buying HYPR shares on the revenue raise announcement date and holding for 30 days yielded an average gain of 12.5%, outperforming the NASDAQ Composite Index’s 7.8% return. This positive performance reflects investor optimism about the company’s growth trajectory, particularly following the next-gen Swoop launch and $20 million October fundraising.

CEO Commentary

Maria Sainz highlighted a 27% sequential revenue rise to $3.4 million and record 53.8% gross margins, driven by next-gen Swoop sales. She emphasized the system’s readiness for “mainstream adoption” and a $20 million funding round extending cash runway to mid-2027. Strategic priorities include expanding into neurology offices and international markets, supported by clinical studies like PRIME and Neuro PMR.

Guidance

Brett Hale projected Q4 2025 revenue of $5–6 million (60% sequential growth) and full-year revenue of $13–14 million. Gross margins are expected to expand to 49%–51% for 2025, with cash burn reduced to $29–31 million, extending the runway to mid-2027.

Additional News

Hyperfine secured a $20.1 million funding round in October 2025, bolstering its cash reserves to $21.6 million as of September 30. The company also launched the PRISM PMR clinical trial to evaluate the next-gen Swoop system in operating rooms, with initial patient enrollment announced on October 21. Additionally, Hyperfine’s Swoop system was referenced in France’s UniHA procurement framework, enabling nationwide adoption in over 1,500 public hospitals. These developments underscore the company’s progress in commercializing its AI-powered portable MRI technology and expanding into international markets.

Rhea-AI Sentiment

End-of-Day -4.55%

Tags: earnings, AI, offering